A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Trial Profile

A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2015

At a glance

  • Drugs Latanoprost/trabodenoson (Primary) ; Latanoprost/timolol
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Inotek Pharmaceuticals
  • Most Recent Events

    • 15 May 2015 According to an Inotek Pharmaceuticals media release, the company expects to complete an End-of-Phase 2 meeting with U.S. FDA during the second quarter of 2015.
    • 15 May 2015 Results are expected in late 2016, according to an Inotek Pharmaceuticals media release.
    • 01 Apr 2015 According to the Inotek Pharmaceuticals media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top